Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Binding of /sup 125/I-labeled recombinant beta interferon (IFN-beta Ser17) to human cells

Journal Article · · Mol. Cell. Biol.; (United States)

The authors investigated the binding of /sup 125/I-labeled beta interferon (IFN-beta Ser17), a nonglycosylated recombinant human fibroblast interferon in which cysteine at position 17 is replaced by serine by site-specific mutagenesis. An optimized chloramine T radiolabeling method produced a highly labeled, fully active /sup 125/I-IFN suitable for these studies. Unlike the case with the chloramine T method, incorporation of a single mole of Bolton-Hunter reagent into a mole of IFN-beta Ser17 led to nearly complete loss of biological activity. /sup 125/I-IFN-beta Ser17, prepared by the chloramine T method, bound specifically to human lymphoblastoid cells (Daudi) with a dissociation constant of 0.24 nM. The number of binding sites per cell was 4,000. In competition assays, unlabeled beta interferons (native, recombinant IFN-beta Cys17, and various preparations of IFN-beta Ser17) equally displaced labeled IFN-beta Ser17 on Daudi cells. Recombinant IFN-alpha-1 displaced /sup 125/I-IFN-beta binding to Daudi cells less efficiently than did unlabeled native or recombinant beta interferon. However, at the concentrations tested, native gamma interferon showed no competition with /sup 125/I-IFN. The results indicate that IFN-beta Ser17 and native IFN-beta posses similar binding properties.

Research Organization:
Cetus Corp., Emeryville, CA
OSTI ID:
5757350
Journal Information:
Mol. Cell. Biol.; (United States), Journal Name: Mol. Cell. Biol.; (United States) Vol. 4:12; ISSN MCEBD
Country of Publication:
United States
Language:
English